There are three million new cases of cancer in Europe every year  . As a society, we know we need more effective anti-cancer medicines, with fewer side-effects, to offer better outcomes for those living with cancer.
Biopharmaceutical companies are committed to finding ways to fulfil that need and have invested heavily in the research and development of innovative therapies. As a result of that commitment, the number of effective anti-cancer medicines available for patients is growing substantially.
This success also heralds a shift in the way anti-cancer medicines are used. As people live with cancer for longer, there is a rise in the number of patients receiving sequential anti-cancer medicines, including combination therapies, increasingly tailored to meet the specific profile of an individual patient.
As Biopharmaceutical Members of the Collaboration for Oncology Data in Europe (CODE)  ,we believe that not enough is known today about how anti-cancer medicines are actually used in real-world clinical practice. Up to date, reliable information is vital. It not only informs patient care, but may also facilitate the independent development of more flexible payment agreements between payers and Biopharmaceutial companies that help address the challenge of financial sustainability. Such agreements may also better reflect the value of anti-cancer medicines in terms of their clinical benefit to patients, thereby helping to mitigate payers’ and providers’ financial risks.
Driven by these imperatives, CODE is supporting the creation of the Oncology Data Network (ODN). The ODN has been designed to collate anti-cancer medicine usage data for all types of cancer, all patients, and all treatment centres in Europe that wish to join. We believe this initiative is a source of valuable information to the oncology community in treating patients, and could provide an important contribution to our independent development of new kinds of flexible agreements based on real world usage of innovative anti-cancer medicines.
Our membership of CODE is a demonstration of our commitment to working with key stakeholders in healthcare systems to encourage the provision of timely information that can inform patient care and proactively address the issue of financial sustainability confronting the oncology community. As the Biopharmaceutical members of CODE, acting independently of one another, we each intend to propose new flexible payment models to help address the financial considerations associated with the use of anti-cancer medicines.
We all share an enduring commitment to research and innovation with the goal of making a significant contribution to the lives of people living with cancer. Together, through our support for the ODN, we are taking a proactive step towards ensuring the long-term financial sustainability of innovative anti-cancer medicines, whilst also providing healthcare systems across Europe with information that informs patient care.
 World Health Organization (WHO) Europe Region, Cancer, data and statistics (http://www.euro.who.int/en/health-topics/noncommunicable-diseases/cancer/data-and-statistics)
 The Biopharmaceutical Members of CODE are: AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Co, Merck and Pfizer